Skip to main navigation
  • Contact
Aimmune
Menu CLOSE X
CLOSE X
  • About Aimmune
    • Company Overview
    • History
    • Leadership
    • Culture of Integrity
  • Our Product
    • Our Product
    • Expanded Access Policy
  • Our Pipeline
    • Our Pipeline
    • Our Focus
  • Investors & Media
    • Investor Overview
    • Press Releases
    • Financials & Filings
      • Annual Reports
      • SEC Filings
    • Corporate Governance
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Investor FAQs
  • Careers
    • Career Opportunities
  • Contact

Press Releases

Keyword Search

Recent News

More news releases are coming soon.

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2

Investor and Media Contacts

Investors

DeDe Sheel
650-376-6492
dsheel@aimmune.com

Media

Julie Normart
559-974-3245
jnormart@w2ogroup.com

Lauren Barbiero
646-564-2156
lbarbiero@w2ogroup.com

Shareholder Tools

  • Print Page
  • Email Alerts
  • IR Contact
  • RSS Feeds
About Aimmune
  • Company Overview
  • History
  • Leadership
  • Culture of Integrity
Investors & Media
  • Investor Overview
  • Press Releases
  • Financials & Filings
  • Corporate Governance
  • Stock Information
  • Investor FAQs
Careers
  • Career Opportunities
© 2019 Aimmune Therapeutics. All rights reserved.
  •  
  • Terms of Use
  • Privacy Policy
  • Privacy Shield
  • Twitter Guidelines
  • Facebook Guidelines
ShareThis Copy and Paste
Aimmune Therapeuticsat the Bank of America Merrill Lynch Healthcare Conference
Tuesday, May 16, 2017 1:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
— "Real-World" Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif.--(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patient...